Krystal Biotech, Inc. — fact timeline

Krystal Biotech, Inc. shareholders approved Non-Employee Director Compensation Policy at the 2026-05-15 meeting.

“The Company’s unaffiliated stockholders (i.e., excluding the members of the the Company’s board of directors and the defendants in the litigation entitled Corbin v. Janney, et al. , C.A. No. 2025-1051-KSJM (Del. Ch.) who refrained from voting on this matter in their capacities as stockholders) approved the Company’s Non-Employee Director Compensation Policy. The results of the vote were as follows: Votes For Votes Against Abstentions Broker Non-Votes 21,374,021 2,349,550 3,158,543 1,581,473”

Krystal Biotech, Inc. shareholders approved Non-Binding, Advisory Vote on Named Executive Officer Compensation at the 2026-05-15 meeting.

“The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers for the fiscal year ended December 31, 2025, as disclosed in the Company’s proxy statement for the Annual Meeting pursuant to the compensation disclosure rules of the Securities and Exchange Commission. The results of the vote were as follows: Votes For Votes Against Abstentions Broker Non-Votes 25,679,318 1,195,788 7,008 1,581,473”

Krystal Biotech, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-05-15 meeting.

“The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the vote were as follows: Votes For Votes Against Abstentions 28,443,155 15,434 4,998”

Krystal Biotech, Inc. shareholders approved Election of Class III Directors at the 2026-05-15 meeting.

“The Company’s stockholders elected Krish S. Krishnan and Christopher Mason as members of the Company’s Board of Directors as Class III directors for a three-year term. The results of the vote were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Krish S. Krishnan 23,802,920 3,079,194 1,581,473 Christopher Mason 22,581,854 4,300,260 1,581,473”

Krystal Biotech, Inc. reported first quarter ending March 31, 2026 results: revenue $116.4 million.

“Krystal Biotech Announces First Quarter 2026 Financial and Operating Results $116.4 million in 1Q VYJUVEK global revenue and $846.7 million since launch”

Krystal Biotech, Inc. reported the first quarter ending March 31, 2024 results: revenue $45.3 million.

“The Company recorded $45.3 million in VYJUVEK net product revenue for the first quarter of 2024.”

Krystal Biotech, Inc. reported the quarter and year ended December 31, 2023 results: revenue $42.1M in 4Q and $50.7M for the year.

“in such filing. --- EX-99.1 (EX-99.1) --- Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates • Net product revenue of $42.1M in 4Q and $50.7M for the year • New England Journal of Medicine publication of the use of B-VEC eyedrop formulation • Reached alignment with FDA to enable approval of B-VEC”

Krystal Biotech, Inc. reported financial results for the quarter ending September 30, 2023.

“On November 6, 2023, Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter ending September 30, 2023.”

Krystal Biotech, Inc. reported financial results for the second quarter ended June 30, 2023.

“On August 7, 2023, Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter ending June 30, 2023.”

Andrew Orth resigned as Chief Commercial Officer at Krystal Biotech, Inc..

“Andrew Orth, the Company’s Chief Commercial Officer, notified the Company that he was resigning from his position and his last day with the Company was August 2, 2023.”

Krystal Biotech, Inc. shareholders approved Non-Binding, Advisory Vote On Named Executive Officer Compensation at the 2023-05-19 meeting.

“Proposal Three: Non-Binding, Advisory Vote On Named Executive Officer Compensation The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers for the fiscal year ended December 31, 2022, as disclosed in the Company’s proxy statement for the Annual Meeting pursuant to the compensation disclosure rules of the Securities and Exchange Commission. The results of the vote were as follows: Votes For Votes Against Abstentions Broker Non-Votes 18,759,786 907,235 7,389 2,431,170”

Krystal Biotech, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-05-19 meeting.

“Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the vote were as follows: Votes For Votes Against Abstentions 22,098,460 2,547 4,573”

Krystal Biotech, Inc. shareholders approved Election of Class III Directors at the 2023-05-19 meeting.

“Proposal One: Election of Class III Directors The Company’s stockholders elected Krish S. Krishnan, Kirti Ganorkar, and Christopher Mason as members of the Company’s Board of Directors as Class III directors for a three-year term. The results of the vote were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Krish S. Krishnan 15,620,498 4,053,912 2,431,170 Kirti Ganorkar 14,761,072 4,913,338 2,431,170 Christopher Mason 15,864,807 3,809,603 2,431,170”

Krystal Biotech, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at approximately $160 million (effective 2023-05-21).

“On May 21, 2023, Krystal Biotech, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (collectively, the “Investors”) to issue and sell at closing an aggregate of 1,729,729 shares of common stock of the Company, par value $0.00001 per share (the “Common Stock”), at a price of $92.50 per share for an aggregate purchase price of approximately $160 million (the “Investment”).”

Krystal Biotech, Inc. reported the quarter ended March 31, 2023 results: net income Net losses for the quarters ended March 31, 2023 and 2022 were $45.3 million and $50.0 million, or $(1.76) and $(1.99),, EPS $(1.76) and $(1.99), respectively, per common share (basic and diluted).

“Net losses for the quarters ended March 31, 2023 and 2022 were $45.3 million and $50.0 million, or $(1.76) and $(1.99), respectively, per common share (basic and diluted).”

Krystal Biotech, Inc. entered into Sales Agreement with Cowen and Company, LLC valued at up to $150.0 million (effective 2023-05-08).

“On May 8, 2023, Krystal Biotech, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”) to issue and sell shares of the Company’s common stock, par value $0.00001 per share, having an aggregate offering price of up to $150.0 million (the “Placement Shares”) from time to time during the term of the Sales Agreement, through an “at-the-market” equity offering program under which Cowen will act as the Company’s agent and/or principal.”

Catherine Mazzacco was appointed as independent member of the Board at Krystal Biotech, Inc..

“On March 6, 2023, the Board of Directors (the “Board”) of Krystal Biotech, Inc. (the “Company”) approved an increase in the size of the Board from eight (8) directors to nine (9) directors and appointed Catherine Mazzacco as an independent member of the Board to fill the vacancy created by the increase in the size of the Board.”

Krystal Biotech, Inc. reported the year ended December 31, 2022 results: net income $140.0 million, EPS $(5.49).

“Net losses for the years ended December 31, 2022 and 2021 were $140.0 million and $69.6 million, or $(5.49) and $(3.13), respectively, per common share (basic and diluted).”

Krystal Biotech, Inc. reported the fourth quarter ended December 31, 2022 results: net income $32.1 million, EPS $(1.25).

“Net losses for the quarters ended December 31, 2022 and 2021 were $32.1 million and $21.8 million, or $(1.25) and $(0.94) respectively, per common share (basic and diluted).”

Krystal Biotech, Inc. reported the third quarter ended September 30, 2022 results: net income $29.9 million, EPS $(1.17) per common share (basic and diluted).

“Net losses for the quarters ended September 30, 2022 and 2021 were $29.9 million and $15.6 million, or $(1.17) and $(0.70), respectively, per common share (basic and diluted).”

Suma M. Krishnan was appointed as President, R&D at Krystal Biotech, Inc..

“Effective February 25, 2022, the board of directors of the Company appointed Ms. Suma M. Krishnan, the Company's current Chief Operating Officer, as the Company's President, R&D.”

E. Rand Sutherland was appointed as Director at Krystal Biotech, Inc..

“On January 13, 2022, the Board appointed E. Rand Sutherland as a member of the Board, effective January 18, 2022, to fill the vacancy created by Dr. Marantz’s resignation.”

Jing Marantz was appointed as Chief Business Officer at Krystal Biotech, Inc..

“Dr. Marantz will continue to serve as a director of the Company until January 18, 2022, subsequent to which, she has agreed to commence a senior executive position (Chief Business Officer) at the Company.”

Jing Marantz resigned as Director at Krystal Biotech, Inc..

“On January 12, 2022, Jing Marantz gave notice of her resignation from the Board of Directors (the “Board”) of Krystal Biotech, Inc. (the “Company”).”